[Genes involved in breast cancers].

Abstract excerpt

Specific abnormalities in cancers are the best molecular targets of therapeutics, which is exemplified by trastuzumab. ERBB2 amplification is present in 15-30% of invasive ductal carcinomas, and its overexpression was associated with poor prognosis. c-MYC amplification is present in 13-19%, but other forms of oncogene activation are rare. Germline mutations of BRCA1 and BRCA2 are responsible for familial breast...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Neoplasms
• Share to DNA Methylation
• Share to Gene Amplification